Redx Pharma PLCLSE Redx Pharma Stock Report

Redx Pharma Plc engages in the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. The company is headquartered in Macclesfield, Cheshire. The company went IPO on 2015-03-27. The Company’s product pipeline includes RXC004 and ROC007. Its lead product candidate, RXC004, which is a potent and selective, orally active once-daily Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer. RXC004 is in Phase I study in combination with nivolumab, an anti-PD1 antibody. The RXC007 is a selective and orally available small molecule inhibitor of Rho-Associated Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signaling pathway.